Levofloxacin is a broad-spectrum fluoroquinolone antibiotic that kills a wide range of bacteria, including many gram-positive, gram-negative, and atypical species. It works by blocking an enzyme called DNA gyrase that bacteria need to copy their DNA and grow. Without this enzyme, bacterial cells can’t replicate and the infection dies off. This broad mechanism is what gives levofloxacin its unusually wide coverage compared to many other antibiotics.
Gram-Positive Bacteria
Levofloxacin is effective against several common gram-positive species. These are the bacteria that cause many everyday infections, from skin wounds to strep throat to pneumonia. According to the FDA-approved labeling, levofloxacin covers:
- Streptococcus pneumoniae, including multi-drug resistant strains. This is one of the most common causes of bacterial pneumonia, sinus infections, and ear infections. Levofloxacin’s ability to handle drug-resistant strains makes it especially useful when first-line antibiotics fail.
- Streptococcus pyogenes, the bacterium behind strep throat, certain skin infections, and scarlet fever.
- Staphylococcus aureus, but only methicillin-susceptible strains. Levofloxacin does not reliably treat MRSA.
- Staphylococcus epidermidis (methicillin-susceptible strains), a common cause of infections on medical devices and implants.
- Staphylococcus saprophyticus, a frequent cause of urinary tract infections in younger women.
- Enterococcus faecalis, though many strains are only moderately susceptible, so it’s not always a reliable choice for enterococcal infections.
Gram-Negative Bacteria
Gram-negative bacteria tend to be harder to treat because of their extra outer membrane, which blocks many antibiotics from getting inside. Levofloxacin penetrates this barrier effectively and covers a long list of gram-negative pathogens:
- Escherichia coli, the leading cause of urinary tract infections and a common culprit in abdominal infections.
- Klebsiella pneumoniae, which causes pneumonia and bloodstream infections, particularly in hospital settings.
- Haemophilus influenzae and Haemophilus parainfluenzae, frequent causes of bronchitis, sinus infections, and ear infections.
- Moraxella catarrhalis, another common respiratory pathogen.
- Pseudomonas aeruginosa, a notoriously difficult-to-treat bacterium associated with hospital-acquired pneumonia, wound infections, and infections in people with cystic fibrosis.
- Proteus mirabilis, a cause of urinary tract infections, especially catheter-related ones.
- Enterobacter cloacae and Serratia marcescens, both found in hospital-acquired infections of the lungs, urinary tract, and bloodstream.
The inclusion of Pseudomonas sets levofloxacin apart from many oral antibiotics. Most pills you can take at home don’t touch Pseudomonas, which is why levofloxacin is sometimes chosen specifically for that coverage.
Atypical Bacteria
Some bacteria don’t show up on standard lab cultures and live inside your cells rather than floating freely. These “atypical” pathogens cause a significant share of pneumonia cases and are notoriously missed by older antibiotics like penicillin. Levofloxacin handles three key atypical species:
- Legionella pneumophila, the cause of Legionnaires’ disease, a severe form of pneumonia contracted from contaminated water systems.
- Mycoplasma pneumoniae, a common cause of “walking pneumonia,” particularly in younger adults and children. Notably, levofloxacin remains effective against strains that have developed resistance to macrolide antibiotics like azithromycin.
- Chlamydia pneumoniae (now called Chlamydophila pneumoniae), another frequent cause of mild-to-moderate pneumonia and bronchitis.
This triple atypical coverage is one reason levofloxacin is sometimes called a “respiratory fluoroquinolone.” It can treat pneumonia as a single drug without needing to combine two antibiotics to cover both typical and atypical causes.
Infections Levofloxacin Is Used For
Because of its broad bacterial coverage, levofloxacin is FDA-approved for a wide range of infections. Community-acquired pneumonia is one of the most common uses, with treatment courses typically lasting 5 to 14 days depending on severity. It’s also approved for hospital-acquired pneumonia, where the bacterial suspects tend to be tougher organisms like Pseudomonas and Klebsiella.
Beyond the lungs, levofloxacin treats complicated and uncomplicated urinary tract infections, acute bacterial sinusitis, chronic bronchitis flare-ups, and certain skin infections. Its ability to reach high concentrations in both lung tissue and urine makes it versatile across these different infection sites.
Resistance Is a Growing Concern
Levofloxacin doesn’t work against every strain of the bacteria listed above. Resistance has been climbing for years, particularly among gram-negative species. European surveillance data from 2019 found that nearly 24% of E. coli isolates were resistant to fluoroquinolones like levofloxacin. That means roughly one in four E. coli urinary tract infections may not respond to this drug.
Resistance rates vary by region and by bacteria. Streptococcus pneumoniae resistance to fluoroquinolones remains relatively low in most countries, which is why levofloxacin is still a reliable option for pneumonia. But for urinary tract infections caused by E. coli, doctors increasingly rely on urine culture results before prescribing it rather than using it as a first guess.
What Levofloxacin Does Not Cover
Levofloxacin has gaps. It does not treat MRSA (methicillin-resistant Staphylococcus aureus), which requires different antibiotics entirely. It is not effective against anaerobic bacteria, the type that thrive in oxygen-free environments like deep abdominal abscesses. Infections caused by certain highly resistant gram-negative organisms, particularly some strains of Pseudomonas and carbapenem-resistant Enterobacteriaceae, may also be beyond its reach. And like all antibiotics, it does nothing against viruses, fungi, or parasites.